Table 3.
Overall (N = 397) | Hispanic (N = 96) | Non-Hispanic White (N = 301) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Outcome | <18 | 18–40.5 | >40.5 | p-trend | <18 | 18–40.5 | >40.5 | p-trend | 0 | >0–6.9 | >6.9 | p-trend |
All-cause death | ||||||||||||
No. of deaths/No. of participants | 56/148 | 37/123 | 40/126 | 12/32 | 8/26 | 10/38 | 44/116 | 29/97 | 30/88 | |||
Model 1§ | ||||||||||||
HR | 1 | 0.73 | 0.77 | 0.18 | 1 | 0.66 | 0.59 | 0.23 | 1 | 0.76 | 0.81 | 0.34 |
95% CI | (0.48, 1.11) | (0.51, 1.15) | (0.27, 1.65) | (0.26, 1.37) | (0.47, 1.21) | (0.51, 1.29) | ||||||
Model 2¶ | ||||||||||||
HR | 1 | 0.72 | 0.76 | 0.17 | 1 | 0.32 | 0.41 | 0.08 | 1 | 0.78 | 0.80 | 0.34 |
95% CI | (0.47, 1.10) | (0.50, 1.14) | (0.11, 0.95) | (0.17, 1.01) | (0.48, 1.27) | (0.50, 1.29) | ||||||
Breast cancer death | ||||||||||||
No. of deaths/No. of participants | 23/148 | 13/123 | 17/126 | 8/32 | 3/26 | 5/38 | 15/116 | 10/97 | 12/88 | |||
Model 1§ | ||||||||||||
HR | 1 | 0.66 | 0.85 | 0.57 | 1 | 0.46 | 0.49 | 0.2 | 1 | 0.77 | 1.04 | 0.06 |
95% CI | (0.33, 1.31) | (0.45, 1.60) | (0.12, 1.76) | (0.16, 1.50) | (0.35, 1.72) | (0.49, 2.24) | ||||||
Model 2¶ | ||||||||||||
HR | 1 | 0.63 | 0.82 | 0.50 | 1 | 0.29 | 0.41 | 0.14 | 1 | 0.76 | 1.05 | 0.08 |
95%CI | (0.32, 1.26) | (0.43, 1.55) | (0.06, 1.34) | (0.12, 1.34) | (0.33, 1.74) | (0.49, 2.25) | ||||||
Non-breast cancer death | ||||||||||||
No. of deaths/No. of participants | 33/148 | 24/123 | 23/126 | 4/32 | 5/26 | 5/38 | 29/116 | 19/97 | 18/88 | |||
Model 1§ | ||||||||||||
HR | 1 | 0.83 | 0.8 | 0.39 | 1 | 0.94 | 0.89 | 0.87 | 1 | 0.83 | 0.78 | 0.40 |
95% CI | (0.49, 1.41) | (0.47, 1.36) | (0.24, 3.63) | (0.24, 3.34) | (0.46, 1.49) | (0.43, 1.42) | ||||||
Model 2¶ | ||||||||||||
HR | 1 | 0.85 | 0.79 | 0.40 | 1 | 0.50 | 0.62 | 0.67 | 1 | 0.85 | 0.74 | 0.33 |
95% CI | (0.49, 1.47) | (0.46, 1.37) | (0.09, 2.73) | (0.13, 2.85) | (0.46, 1.57) | (0.40, 1.36) |
§Models adjusted for age and ethnicity (among all women) only.
¶Models adjusted for age, disease stage at baseline, treatment, BMI, diabetes, fructosamine, and ethnicity (among all women).